TrialBMC cancer2015

Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.

Mark Thalgott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.